{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:21:01Z","timestamp":1793928061555,"version":"4.8.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1038\/s41431-022-01098-7","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T04:04:04Z","timestamp":1652069044000},"page":"818-823","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["The genetics of hereditary cancer risk syndromes in Brazil: a comprehensive analysis of 1682 patients"],"prefix":"10.1038","volume":"30","author":[{"given":"Jarbas Maciel","family":"de Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria Bengala","family":"Zurro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2143-9701","authenticated-orcid":false,"given":"Antonio Victor Campos","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel Pinheiro","family":"Caraciolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Bertollo","family":"de Alexandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8146-5798","authenticated-orcid":false,"given":"Murilo Castro","family":"Cervato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata Moldenhauer","family":"Minillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"de Vasconcelos Carvalho Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Grivicich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Bosco","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"key":"1098_CR1","doi-asserted-by":"publisher","first-page":"6445","DOI":"10.1038\/sj.onc.1207714","volume":"23","author":"R Nagy","year":"2004","unstructured":"Nagy R, Sweet K, Eng C. Highly penetrant hereditary cancer syndromes. Oncogene. 2004;23:6445\u201370.","journal-title":"Oncogene."},{"key":"1098_CR2","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324.","journal-title":"Genet Med."},{"key":"1098_CR3","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1038\/gim.2018.42","volume":"20","author":"LG Biesecker","year":"2018","unstructured":"Biesecker LG, Harrison SM. ClinGen Sequence Variant Interpretation Working G. The ACMG\/AMP reputable source criteria for the interpretation of sequence variants. Genet Med. 2018;20:1687\u20138.","journal-title":"Genet Med."},{"key":"1098_CR4","doi-asserted-by":"crossref","unstructured":"Yoshida R. Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis. Breast Cancer. 2020;28:1167\u201380.","DOI":"10.1007\/s12282-020-01148-2"},{"key":"1098_CR5","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/gim.2015.166","volume":"18","author":"LR Susswein","year":"2016","unstructured":"Susswein LR, Marshall ML, Nusbaum R, Vogel Postula KJ, Weissman SM, Yackowski L, et al. Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. Genet Med. 2016;18:823\u201332.","journal-title":"Genet Med."},{"key":"1098_CR6","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jmoldx.2019.03.001","volume":"21","author":"CL Neben","year":"2019","unstructured":"Neben CL, Zimmer AD, Stedden W, van den Akker J, O\u2019Connor R, Chan RC, et al. Multi-gene panel testing of 23,179 individuals for hereditary cancer risk identifies pathogenic variant carriers missed by current genetic testing guidelines. J Mol Diagn. 2019;21:646\u201357.","journal-title":"J Mol Diagn."},{"key":"1098_CR7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cancergen.2016.06.008","volume":"209","author":"B Alemar","year":"2016","unstructured":"Alemar B, Herzog J, Brinckmann Oliveira Netto C, Artigal\u00e1s O, Schwartz IVD, Matzenbacher Bittar C, et al. Prevalence of Hispanic BRCA1 and BRCA2 mutations among hereditary breast and ovarian cancer patients from Brazil reveals differences among Latin American populations. Cancer Genet. 2016;209:417\u201322.","journal-title":"Cancer Genet"},{"key":"1098_CR8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1590\/S1415-47572012000400009","volume":"35","author":"CV Dillenburg","year":"2012","unstructured":"Dillenburg CV, Bandeira IC, Tubino TV, Rossato LG, Dias ES, Bittelbrunn AC, et al. Prevalence of 185delAG and 5382insC mutations in BRCA1, and 6174delT in BRCA2 in women of Ashkenazi Jewish origin in southern Brazil. Genet Mol Biol. 2012;35:599\u2013602.","journal-title":"Genet Mol Biol"},{"key":"1098_CR9","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s12282-018-00938-z","volume":"26","author":"NM Cipriano Jr.","year":"2019","unstructured":"Cipriano NM Jr., de Brito AM, de Oliveira ES, de Faria FC, Lemos S, Rodrigues AN, et al. Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil. Breast Cancer. 2019;26:397\u2013405.","journal-title":"Breast Cancer"},{"key":"1098_CR10","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s10038-020-00849-y","volume":"66","author":"M Okano","year":"2021","unstructured":"Okano M, Nomizu T, Tachibana K, Nagatsuka M, Matsuzaki M, Katagata N, et al. The relationship between BRCA-associated breast cancer and age factors: an analysis of the Japanese HBOC consortium database. J Hum Genet. 2021;66:307\u201314.","journal-title":"J Hum Genet"},{"key":"1098_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-27315-2","volume":"8","author":"EI Palmero","year":"2018","unstructured":"Palmero EI, Carraro DM, Alemar B, Moreira MAM, Ribeiro-Dos-Santos A, Abe-Sandes K, et al. The germline mutational landscape of BRCA1 and BRCA2 in Brazil. Sci Rep. 2018;8:9188.","journal-title":"Sci Rep."},{"key":"1098_CR12","doi-asserted-by":"crossref","unstructured":"Rebbeck TR, Friebel TM, Mitra N, Wan F, Chen S, Andrulis IL, et al. Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research. 2016;18:112.","DOI":"10.1186\/s13058-016-0768-3"},{"key":"1098_CR13","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1136\/jmg.2004.027243","volume":"42","author":"B Leegte","year":"2005","unstructured":"Leegte B, van der Hout AH, Deffenbaugh AM, Bakker MK, Mulder IM, ten Berge A, et al. Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations. J Med Genet. 2005;42:e20.","journal-title":"J Med Genet"},{"key":"1098_CR14","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/annonc\/mdq460","volume":"22","author":"O Lavie","year":"2011","unstructured":"Lavie O, Narod S, Lejbkowicz F, Dishon S, Goldberg Y, Gemer O, et al. Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population. Ann Oncol. 2011;22:964\u20136.","journal-title":"Ann Oncol"},{"key":"1098_CR15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s10549-010-0853-8","volume":"124","author":"M Zuradelli","year":"2010","unstructured":"Zuradelli M, Peissel B, Manoukian S, Zaffaroni D, Barile M, Pensotti V, et al. Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics. Breast Cancer Res Treat. 2010;124:251\u20138.","journal-title":"Breast Cancer Res Treat"},{"key":"1098_CR16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10549-011-1718-5","volume":"131","author":"JM Noh","year":"2012","unstructured":"Noh JM, Choi DH, Nam SJ, Lee JE, Kim JW, Kim SW, et al. Characteristics of double heterozygosity for BRCA1 and BRCA2 germline mutations in Korean breast cancer patients. Breast Cancer Res Treat. 2012;131:217\u201322.","journal-title":"Breast Cancer Res Treat."},{"key":"1098_CR17","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10549-014-2971-1","volume":"145","author":"AP Sokolenko","year":"2014","unstructured":"Sokolenko AP, Bogdanova N, Kluzniak W, Preobrazhenskaya EV, Kuligina ES, Iyevleva AG, et al. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN\/NBS1, and BLM germ-line mutations. Breast Cancer Res Treat. 2014;145:553\u201362.","journal-title":"Breast Cancer Res Treat"},{"key":"1098_CR18","doi-asserted-by":"publisher","first-page":"e47993","DOI":"10.1371\/journal.pone.0047993","volume":"7","author":"F Pern","year":"2012","unstructured":"Pern F, Bogdanova N, Sch\u00fcrmann P, Lin M, Ay A, L\u00e4nger F, et al. Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer. PLoS One. 2012;7:e47993.","journal-title":"PLoS One"},{"key":"1098_CR19","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s10689-012-9561-3","volume":"11","author":"NM Lindor","year":"2012","unstructured":"Lindor NM, Smyrk TC, Buehler S, Gunawardena SR, Thomas BC, Limburg P, et al. Multiple jejunal cancers resulting from combination of germline APC and MLH1 mutations. Fam Cancer. 2012;11:667\u20139.","journal-title":"Fam Cancer"},{"key":"1098_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3422-2","volume":"17","author":"EM Grindedal","year":"2017","unstructured":"Grindedal EM, Heramb C, Karsrud I, Ariansen SL, M\u00e6hle L, Undlien DE, et al. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers. BMC Cancer. 2017;17:438.","journal-title":"BMC Cancer"},{"key":"1098_CR21","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1245\/s10434-018-6621-4","volume":"25","author":"S Yang","year":"2018","unstructured":"Yang S, Axilbund JE, O\u2019Leary E, Michalski ST, Evans R, Lincoln SE, et al. Underdiagnosis of hereditary breast and ovarian cancer in medicare patients: genetic testing criteria miss the mark. Ann Surg Oncol. 2018;25:2925\u201331.","journal-title":"Ann Surg Oncol."},{"key":"1098_CR22","doi-asserted-by":"publisher","first-page":"e0187630","DOI":"10.1371\/journal.pone.0187630","volume":"12","author":"B Alemar","year":"2017","unstructured":"Alemar B, Greg\u00f3rio C, Herzog J, Matzenbacher Bittar C, Brinckmann Oliveira Netto C, Artigalas O, et al. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population? PLOS ONE. 2017;12:e0187630.","journal-title":"PLOS ONE"},{"key":"1098_CR23","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1200\/JCO.1996.14.5.1730","volume":"14","author":"American Society of Clinical Oncology.","year":"1996","unstructured":"American Society of Clinical Oncology. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol. 1996;14:1730\u20136. discussion 7-40","journal-title":"J Clin Oncol."},{"key":"1098_CR24","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1200\/JCO.2013.50.9257","volume":"32","author":"KH Lu","year":"2014","unstructured":"Lu KH, Wood ME, Daniels M, Burke C, Ford J, Kauff ND, et al. American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. J Clin Oncol. 2014;32:833\u201340.","journal-title":"J Clin Oncol."},{"key":"1098_CR25","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/sj.bjc.6602175","volume":"91","author":"AC Antoniou","year":"2004","unstructured":"Antoniou AC, Pharoah PP, Smith P, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer. 2004;91:1580\u201390.","journal-title":"Br J Cancer"},{"key":"1098_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1086\/301670","volume":"62","author":"G Parmigiani","year":"1998","unstructured":"Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998;62:145\u201358.","journal-title":"Am J Hum Genet."},{"key":"1098_CR27","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1136\/jmg.2003.017996","volume":"41","author":"DG Evans","year":"2004","unstructured":"Evans DG, Eccles DM, Rahman N, Young K, Bulman M, Amir E, et al. A new scoring system for the chances of identifying a BRCA1\/2 mutation outperforms existing models including BRCAPRO. J Med Genet. 2004;41:474\u201380.","journal-title":"J Med Genet."},{"key":"1098_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.maturitas.2017.06.002","volume":"105","author":"N Teixeira","year":"2017","unstructured":"Teixeira N, Maistro S, Del Pilar Estevez Diz M, Mourits MJ, Oosterwijk JC, Folgueira MAK, et al. Predictability of BRCA1\/2 mutation status in patients with ovarian cancer: How to select women for genetic testing in middle-income countries. Maturitas. 2017;105:113\u20138.","journal-title":"Maturitas."},{"key":"1098_CR29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1200\/JGO.19.00170","volume":"6","author":"MI Achatz","year":"2020","unstructured":"Achatz MI, Caleffi M, Guindalini R, Marques RM, Nogueira-Rodrigues A, Ashton-Prolla P. Recommendations for advancing the diagnosis and management of hereditary breast and ovarian cancer in Brazil. JCO Glob Oncol. 2020;6:439\u201352.","journal-title":"JCO Glob Oncol"},{"key":"1098_CR30","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1590\/1678-4685-gmb-2014-0350","volume":"39","author":"IP Ewald","year":"2016","unstructured":"Ewald IP, Cossio SL, Palmero EI, Pinheiro M, Nascimento IL, Machado TM, et al. BRCA1 and BRCA2 rearrangements in Brazilian individuals with hereditary breast and ovarian cancer syndrome. Genet Mol Biol. 2016;39:223\u201331.","journal-title":"Genet Mol Biol."}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41431-022-01098-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-022-01098-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-022-01098-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T19:07:23Z","timestamp":1657134443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-022-01098-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,9]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1098"],"URL":"https:\/\/doi.org\/10.1038\/s41431-022-01098-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.04.15.21255554","asserted-by":"object"}]},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,9]]},"assertion":[{"value":"29 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This project was approved by the Research Ethics Committee of the Institute of Integral Medicine Professor Fernando Figueira (CEP-IMIP) in Recife, Pernambuco and all individuals provided written consent for multi-gene testing (protocol number 29567220.4.1001.0071).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}